Market Overview:
The global glucagon drug market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of diabetes, rising awareness about glucagon therapy, and technological advancements in the field of glucagon delivery devices. Based on type, the global glucagon drug market can be segmented into injectable and nasal formulations. Injectable formulations are expected to dominate the market during the forecast period owing to their high efficacy and ease of use. However, nasal formulations are anticipated to witness higher growth rates due their potential advantages such as easy administration and reduced side effects as compared with injectable formulations. Based on application, emergency kits are estimated to account for a major share of the global glucagon drug market in 2018 owingto their growing usage for treating severe hypoglycemia episodes among patients with diabetes mellitus (DM). General use is also projectedto register significant growth duringthe forecastperioddue tobenefits such astheir lower costand easy availability as compared with emergency kits.
Product Definition:
A hormone secreted by the pancreas that stimulates the conversion of glycogen to glucose in the liver, raising blood sugar levels. It is used to treat low blood sugar (hypoglycemia).
Inject Glucagon:
Inject glucagon is a recombinant protein that is manufactured by the genetic fusion of the human insulin gene with the DNA for chimaera/glucagon. It has an amino acid sequence similar to that of regular human insulin but with several differences in its structure and function which makes it distinct from regular human insulin.
Nasal Glucagon:
Nasal glucagon is a peptide hormone that stimulates the liver to release glucose into the blood. It's also used as an insulin alternative in some people with type 1 diabetes. The drug was approved by the FDA for sale in the U.S.
Application Insights:
Diagnostic and motility segment held the largest share of glucagon drug application market in 2017. This is due to the growing number of research studies that have proved its utility in diagnosing various diseases such as diabetes, hypoglycemia, and hyperglycemia. General use segment is expected to be fastest-growing glucagon drug application market owing to high demand for emergency kits among diabetic patients.
The cardiogenic shock segment is also projected to grow at lucrative rate during the forecast period owing to rising incidence of heart-related disorders among all age groups across the globe. As per American Heart Association, around 647 thousand deaths occur every year due largely without doubt cardiovascular disease or CVDs are one of leading cause of death globally along with cancer which accounts for around half million deaths annually worldwide making it one of leading cause globally thus fueling growth in this region over next eight years.
Regional Analysis:
North America dominated the global glucagon drug market in 2017. The presence of key players, favorable reimbursement scenario, and increasing demand for innovative products are some of the factors responsible for its largest share. In addition, growing awareness about treatment options among patients is expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising incidences of diabetes in this region coupled with improving healthcare infrastructure and economic development. Moreover, an increase in per capita income has led to a rise in consumer disposable income levels which will further boost product sales over the next eight years (from 2018 to 2030).
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is expected to drive the demand for glucagon drugs in the coming years.
- Growing awareness about glucagon therapy: There is a growing awareness among people about the benefits of glucagon therapy, which is expected to boost the demand for these drugs in the near future.
- Technological advancements: The development of novel and more effective glucagon drugs is likely to fuel market growth in the coming years.
- Rising number of product approvals: The number of product approvals for glucagon therapies has been on the rise in recent years, which is indicative of growing investor confidence in this market space and bodes well for future market growth prospects. 5) Emerging markets offer significant potential growth opportunities: Glucagon drug markets are witnessing strong growth rates across emerging economies such as China and India due to rising incidence rates of diabetes and improving healthcare infrastructure
Scope Of The Report
Report Attributes
Report Details
Report Title
Glucagon Drug Market Research Report
By Type
Inject Glucagon, Nasal Glucagon
By Application
Emergency Kits, General Use, Diagnostic & Motility, Cardiogenic Shock, Others
By Companies
Novo Nordisk, Eli Lilly, Fresenius Kabi, Torrent Labs
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Glucagon Drug Market Report Segments:
The global Glucagon Drug market is segmented on the basis of:
Types
Inject Glucagon, Nasal Glucagon
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Emergency Kits, General Use, Diagnostic & Motility, Cardiogenic Shock, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novo Nordisk
- Eli Lilly
- Fresenius Kabi
- Torrent Labs
Highlights of The Glucagon Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Inject Glucagon
- Nasal Glucagon
- By Application:
- Emergency Kits
- General Use
- Diagnostic & Motility
- Cardiogenic Shock
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glucagon Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glucagon is a hormone that helps the body to convert glucose into energy. Glucagon is used to treat diabetes and other conditions that cause high blood sugar levels.
Some of the major players in the glucagon drug market are Novo Nordisk, Eli Lilly, Fresenius Kabi, Torrent Labs.
The glucagon drug market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Glucagon Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Glucagon Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Glucagon Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Glucagon Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Glucagon Drug Market Size & Forecast, 2020-2028
4.5.1 Glucagon Drug Market Size and Y-o-Y Growth
4.5.2 Glucagon Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Inject Glucagon
5.2.2 Nasal Glucagon
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Emergency Kits
6.2.2 General Use
6.2.3 Diagnostic & Motility
6.2.4 Cardiogenic Shock
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Glucagon Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Glucagon Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Inject Glucagon
9.6.2 Nasal Glucagon
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Emergency Kits
9.10.2 General Use
9.10.3 Diagnostic & Motility
9.10.4 Cardiogenic Shock
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Inject Glucagon
10.6.2 Nasal Glucagon
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Emergency Kits
10.10.2 General Use
10.10.3 Diagnostic & Motility
10.10.4 Cardiogenic Shock
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Inject Glucagon
11.6.2 Nasal Glucagon
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Emergency Kits
11.10.2 General Use
11.10.3 Diagnostic & Motility
11.10.4 Cardiogenic Shock
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Inject Glucagon
12.6.2 Nasal Glucagon
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Emergency Kits
12.10.2 General Use
12.10.3 Diagnostic & Motility
12.10.4 Cardiogenic Shock
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Inject Glucagon
13.6.2 Nasal Glucagon
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Emergency Kits
13.10.2 General Use
13.10.3 Diagnostic & Motility
13.10.4 Cardiogenic Shock
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Glucagon Drug Market: Competitive Dashboard
14.2 Global Glucagon Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Novo Nordisk
14.3.2 Eli Lilly
14.3.3 Fresenius Kabi
14.3.4 Torrent Labs
